MabVax Therapeutics announces the closing of $1.3 million registered direct offering
MabVax Therapeutics announced the close of its securities purchase agreements with investors providing for the registered sale of approximately $1,312,500 of shares of Series J Convertible Preferred Stock, representing approximately 2,386.36 shares at a purchase price of $550 per share. August 22, 2017